BTIG Reiterates Buy Rating on Harrow Health (HROW) ahead of presentations
Tweet Send to a Friend
BTIG analyst Thomas Shrader reiterated a Buy rating and $63.00 price target on Harrow Health (NASDAQ: HROW)The analyst commented, "Harrow ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
